Earnings ·
AbbVie updated its 2025 guidance to include an expected $1.3 billion pre-tax charge for acquired IPR&D and milestone…
ABBVAbbVie Inc.
AbbVie updated its 2025 guidance to include an expected $1.3 billion pre-tax charge for acquired IPR&D and milestone expenses in the fourth quarter, which will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.71. This results in a revised full-year 2025 adjusted diluted EPS guidance range of $9.90 to $9.94, clarifying the significant bottom-line impact of the company's recent acquisitions and collaborations.